Neogen Corporation account plan
Food safety solutions and services
At a glance
Neogen makes food safety diagnostics and animal safety products; FY2026 revenue was $870.4 million with 2,636 employees.
Neogen Corporation (NASDAQ: NEOG, Lansing, Michigan) develops and sells food safety diagnostics, including Petrifilm, culture media, pathogen, allergen and toxin tests and Clean-Trace hygiene monitoring, plus animal safety products such as veterinary instruments, animal care and rodent and insect control. Its customers are food and feed producers, processors, laboratories, regulators, veterinarians and livestock producers, served directly in 28 countries outside the U.S. and through distributors in more than 100 countries. FY2026 (year to May 31, 2026) revenue was $870.4 million and the net loss $7.9 million; sales outside the U.S. were 51.2% of revenue. It had 2,636 employees at May 31, 2026.
Business units
Food Safety
about 74% of FY2026 revenue ($641.1 million)Petrifilm and culture media, Clean-Trace hygiene monitoring, molecular pathogen detection, allergen and mycotoxin tests and the Neogen Analytics software, sold to food and feed producers, processors, labs and regulators. Revenue was flat in FY2026 with $63.4 million of segment operating income, then grew 7.3% to $163.2 million in Q1 FY2027. Tammy Rinalli is General Manager, Global Food Safety.
Animal Safety
about 26% of FY2026 revenue ($229.3 million)Veterinary instruments and disposables, animal care products, rodent and insect control and genomics services for veterinarians, livestock producers and retailers. Revenue fell 11% in FY2026 on divested lines and third-party supplier issues, then grew 4.4% to $59.6 million in Q1 FY2027. The Genomics business is being sold to Zoetis.
Strategic priorities
- Bringing Petrifilm manufacturing in-house
- Petrifilm production moves from 3M plants to Neogen's Lansing site; the first SKU was fully validated in August 2026 and the multi-quarter transition of 17 SKUs starts in November 2026. The CFO talked about 200 to 300 basis points of gross margin expansion once fully ramped.
- Commercial excellence
- A new model under CCO Joe Friels focuses on 14 priority countries, a dedicated strategic account function, solutions-based selling and e-commerce for the long tail; about 40% of Food Safety revenue already flows through e-commerce.
- Rebuilding innovation
- R&D spending rises about 50% in FY2027, with a long-term aim of approaching 5% of revenue, led by CSO Jeremy Yarwood; a Petrifilm innovation line at Oakdale, Minnesota should allow two new Petrifilm SKUs a year.
- Margin expansion and efficiency
- The long-term objective is approximately 30% adjusted EBITDA margins, with $25 million of transformation spending in FY2027 and AI and automation planned in customer service, finance, planning, R&D and technical service.
- Debt reduction
- About $140 million of net Genomics proceeds go to debt reduction and investment, with net leverage targeted close to 2.5 times by the end of FY2027.
Latest results
In Q1 FY2027 (three months to August 31, 2026), revenue was $222.8 million, up 6.5% from $209.2 million, with core growth of 8.1%, about 3% of which came from prior-year distributor inventory adjustments and order timing. Food Safety grew 7.4% and Animal Safety 4.2%, and every region grew. Gross margin rose to 47.4% from 45.4% and adjusted EBITDA was $41.6 million (18.7% margin); the GAAP net loss was $11.9 million. FY2027 guidance was raised to revenue of $885-$890 million and adjusted EBITDA of $181-$183 million.
Investments and deals
- Lansing Petrifilm plant
- The new Lansing facility nears completion; capex was $51.3 million in FY2026 and is estimated at about $40 million in FY2027.
- Cleaners and Disinfectants divestiture
- Sold to Kersia Group in Q1 FY2026 for $121.7 million in cash plus an earnout of up to $3.5 million; proceeds went to debt repayment.
- Genomics divestiture
- Agreed on March 2, 2026 to sell Genomics to Zoetis for $160.0 million; the ACCC and NZCC reviews are expected to conclude by the end of December 2026.
- Hinalea Imaging collaboration
- An equity investment and collaboration to develop hyperspectral digital imaging for food safety and quality inspection, announced with Q1 FY2027 results.
- Sample collection automation
- A new sample collection automation line is planned for fiscal 2028, after sample collection ran at a negative gross margin.
Challenges and risks
- Petrifilm transition risk
- The move from 3M plants may be delayed or run over cost, and duplicative costs continue until it completes ($9.8 million more in Food Safety in FY2026); the 3M agreement runs to August 2027 as a backstop.
- Supplier dependence
- Animal Safety core revenue fell 8.7% in Q3 FY2026 because of third-party supplier disruptions, including an instrument supplier moving sites, the global vitamin A shortage and a sodium bicarb partner.
- Tariffs and input costs
- Tariffs raise costs on imported materials and hurt international sales of U.S.-made products; freight costs rose about $1.5 million per quarter.
- Debt and covenants
- Debt was about $800.0 million at May 31, 2026 against cash of $185.5 million, with covenants on funded debt to EBITDA and debt service coverage.
- Weak end markets and leadership change
- The Animal Safety end market remains near cyclical lows, food producers face inflation, and the 10-K cites significant recent management transitions.
What leadership says
“Build Neogen into the undisputed global food safety category leader.”
“strengthening commercial discipline, harmonizing our sales operating model, rebuilding our innovation engine”
“our challenges are operational. They're internally related.”
“We're going more top to top now”
Where a supplier can help
- Manufacturing ramp support
- Tied to the Petrifilm in-house transition: equipment, validation, quality and automation suppliers can help ramp 17 SKUs in Lansing and the planned sample collection automation line.
- Sales operations and e-commerce tools
- Tied to the commercial excellence priority: CRM, KPI tracking, strategic account and e-commerce platforms fit a model built on priority countries, top-to-top selling and serving the long tail online.
- AI and automation in back-office functions
- Tied to the margin expansion priority: with about 56% of operating expenses in salaries and benefits, AI for customer service, finance and planning addresses a stated cost lever.
- Supplier qualification and sourcing
- Tied to the supplier dependence challenge: alternative or dual sources for instruments and raw materials reduce the disruptions that hit Animal Safety.
- R&D and technology licensing
- Tied to the innovation priority: R&D partners and licensors from adjacent markets such as human healthcare can feed next-generation pathogen detection and sanitation platforms.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Neogen Corporation?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Neogen Corporation Annual Report on Form 10-K for the fiscal year ended May 31, 2026
- Neogen (Lansing, Michigan; NASDAQ: NEOG) makes food safety diagnostics (Petrifilm, culture media, pathogen, allergen and natural toxin tests, Clean-Trace hygiene monitoring, Neogen Analytics software) and animal safety products (veterinary instruments, animal care, rodent and insect control, genomics services).
- FY2026 (year to May 31, 2026): revenue $870.4 million, down from $894.7 million; the drop came from $55.6 million of discontinued product lines, mainly the Cleaners and Disinfectants business sold to Kersia, partly offset by $17.3 million of business growth and $14.0 million of favourable foreign exchange.
- Food Safety revenue was $641.1 million (flat) with segment operating income of $63.4 million; Animal Safety revenue was $229.3 million (down 11%) with operating income of $24.5 million. Net loss was $7.9 million after a $76.4 million gain on the Cleaners and Disinfectants sale (FY2025 net loss of $1,092.0 million included a $1,059.3 million goodwill impairment).
- Portfolio pruning: Cleaners and Disinfectants sold for $121.7 million cash in Q1 FY2026; Genomics business to be sold to Zoetis for $160.0 million, with the ACCC and New Zealand Commerce Commission reviews in second phase.
- Petrifilm manufacturing is moving from 3M plants to Neogen's new Lansing site; the multi-quarter transition is planned to begin in fiscal year 2027, with duplicative costs meanwhile ($9.8 million more in Food Safety in FY2026).
- A Q2 FY2026 restructuring cut about 10% of global headcount; 2,636 employees at May 31, 2026 (817 in sales and marketing, 89 in R&D).
- FY2027 plan: a growth strategy built on commercial excellence, innovation and operational efficiency; capex expected at about $40 million (FY2026: $51.3 million).
- Debt of about $800.0 million at year end (term loan $405.0 million, senior notes $346.5 million, revolver $48.5 million) against cash of $185.5 million; $20.0 million of the term loan was repaid after year end.
- Sales outside the U.S. were 51.2% of revenue; key risks are the Petrifilm transition, tariffs, supplier dependence, debt covenants and recent management transitions.
- Neogen Corporation Quarterly Report on Form 10-Q for the quarter ended August 31, 2026 (Q1 FY2027)
- Q1 FY2027 (three months to August 31, 2026): revenue of $222.8 million, up from $209.2 million, with $16.9 million of business growth and $1.6 million of FX, less $4.9 million from the Cleaners and Disinfectants divestiture and discontinued lines.
- Food Safety revenue was $163.2 million (+7.3%) and operating income $16.3 million (up from $7.2 million). Animal Safety revenue was $59.6 million (+4.4%) and operating income $7.5 million (up from $4.5 million).
- Gross margin improved to 47.4% from 45.4% on volume, price and FX, partly offset by duplicative Petrifilm costs.
- The operating loss narrowed to $1.8 million (from $16.1 million). The net loss was $11.9 million, against net income of $36.3 million a year earlier, which included a $76.4 million divestiture gain.
- The growth strategy (commercial excellence, innovation, operational efficiency) started this quarter; R&D spending rose to $6.5 million from $5.1 million.
- Genomics sale to Zoetis: the ACCC and NZCC reviews are expected to conclude by the end of December 2026.
- Cash was $172.0 million. A further $20.0 million of the term loan was prepaid in the quarter and $10.0 million after it; FY2027 capex is estimated at about $40.0 million.
- Neogen Reports First-Quarter Financial Results for Fiscal Year 2027 (press release, Exhibit 99.1)
- Q1 FY2027 revenue was $222.8 million, up 6.5%, with core growth of 8.1%; about 3% of that core growth came from prior-year distributor inventory adjustments and order timing.
- Food Safety revenue was $163.2 million (+7.4%, core +8.1%), led by Indicator Testing and Culture Media (including Petrifilm) and pathogen detection. Animal Safety revenue was $59.6 million (+4.2%, core +8.0%).
- Adjusted EBITDA was $41.6 million (18.7% margin, from 17.0%). Adjusted EPS was $0.08; GAAP net loss $11.9 million.
- Operating cash flow was $12.9 million and free cash flow $4.7 million.
- FY2027 guidance raised to revenue of $885-$890 million (from $880-$885 million) and adjusted EBITDA of $181-$183 million (from $180-$182 million).
- Petrifilm: the first SKU was fully validated in August 2026, and the multi-quarter transition to Lansing starts in November 2026.
- Neogen made an equity investment in Hinalea Imaging and entered a collaboration with it on hyperspectral digital imaging for food inspection.
- CEO Mike Nassif: the focus "shifted from strengthening fundamentals to scaling them".
- Neogen Q4 and full-year fiscal 2026 earnings call transcript
- CEO Mike Nassif: the ambition is to "Build Neogen into the undisputed global food safety category leader". FY2026 was about "stabilization and foundation building"; FY2027 is about accelerating profitable growth.
- Q4 FY2026 revenue was $225.3 million with 4.3% core growth, the year's best. Food Safety core growth reached 5.8%, the highest since 2023. Animal Safety returned to positive core growth and grew 7% sequentially.
- FY2027 guidance: revenue of $880-$885 million and adjusted EBITDA of $180-$182 million (20.5% margin at the midpoint), including about $92 million of revenue and $13 million of EBITDA from Genomics. Implied core growth is about 3%.
- Three priorities: commercial prowess, high-impact innovation and operational efficiency. R&D spending rises about 50% in FY2027, with a long-term aim of approaching 5% of revenue.
- New commercial model (CCO Joe Friels): 14 priority countries, a dedicated strategic account function, solutions instead of products, and e-commerce for the long tail. About 40% of Food Safety revenue already flows through e-commerce.
- Petrifilm: the first SKU is to be fully validated in August, and the transition starts November 2026; the CFO talked about 200 to 300 basis points of gross margin expansion once the line is fully ramped.
- The long-term objective is approximately 30% adjusted EBITDA margins. Transformation spending is $25 million in FY2027.
- The roughly $140 million of net Genomics proceeds will go to debt reduction and investment; net leverage is targeted near 2.5 times by the end of FY2027.
- Neogen Q3 fiscal 2026 earnings call transcript
- Q3 FY2026 revenue was $211.2 million (0.1% core growth). Food Safety revenue was $156.7 million with 4% core growth; Animal Safety revenue was $54.5 million, with core revenue down 8.7% on third-party supplier disruptions.
- Adjusted EBITDA was $48.2 million at a 22.8% margin, which Nassif called among the highest in recent company history, achieved through cost discipline.
- Three initiatives: commercial prowess (a solutions-based selling model under new leaders Tammy Rinalli and Joe Friels), high-impact innovation (led by CSO Jeremy Yarwood) and operational efficiency.
- Petrifilm: 100% of the production equipment is validated, validation of all 17 SKUs has started and the November 2026 transition is on schedule; the 3M agreement runs to August 2027 as "insurance".
- The animal safety supply issues came from an instrument supplier moving sites to reduce tariffs, the global vitamin A shortage and a sodium bicarb partner.
- Genomics is being sold for $160 million (about $140 million net); the unit had about $90 million of FY2025 revenue at mid-teens adjusted EBITDA margins, and the sale is accretive.
- About 56% of operating expenses are salaries and benefits; AI and automation are planned in customer service, finance, S&OP, R&D and technical service.
- FY2026 revenue guidance was raised to $857-$860 million, with adjusted EBITDA held at $175 million.
Questions about Neogen Corporation
What does Neogen do?
Neogen makes food safety diagnostics such as Petrifilm, culture media, pathogen and allergen tests, and animal safety products such as veterinary instruments and rodent and insect control.
What is Neogen's revenue?
FY2026 revenue (year to May 31, 2026) was $870.4 million. FY2027 revenue is guided at $885-$890 million.
How many employees does Neogen have?
Neogen had 2,636 employees at May 31, 2026, after a restructuring that cut about 10% of global headcount.
Who leads Neogen?
Mikhael Nassif is President and CEO, R. Bryan Riggsbee is CFO and James C. Borel is Chairman of the Board.
What is Neogen's strategy?
Neogen's FY2027 plan rests on commercial excellence, innovation and operational efficiency, with Petrifilm manufacturing moving in-house and the Genomics business being sold to Zoetis.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)